ArticleFrontiers in medicine2025
Inhibition of lens-induced myopia in guinea pigs using a far-induced infrared ray material.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Numerous studies have demonstrated a close relationship between choroidal thickness (ChT), sclera/choroidal hypoxia, and the onset and progression of myopia. Far-infrared (FIR) therapy is a traditional method used to enhance microcirculation. In this study, we estimated the effectiveness of FIR in myopia control and explored its underlying mechanisms. Furthermore, we compared the efficacy of FIR from two different sources in controlling myopia. Methods: Guinea pigs were divided into three groups, all of which underwent minus lens induction for 4 weeks. Two of the groups received simultaneous FIR intervention, either from a FIR radiator (FIRR) lamp or from an innovative FIR material (FIRM). Refraction, axial length (AL), ChT, and levels of hypoxia-labeled pimonidazole in the choroid and sclera were measured. Results: Both FIRR and FIRM inhibited increases in refraction and AL and attenuate the decrease in ChT. They also mitigated choroidal and scleral hypoxia. Compared to FIRR, FIRM demonstrated a greater effect on myopia control and hypoxia attenuation. However, the difference in AL reduction between the two FIR sources was not statistically significant. Conclusion: FIR effectively controls myopia, and the innovative FIR material may represent a breakthrough in myopia management in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.